OncLive - Clinical Oncology News, Cancer Expert Insights
OncLive - Clinical Oncology News, Cancer Expert Insights
Spotlight
OncClub: Join the Chat on Trending Trials in CancerComplimentary print subscription for home or office deliveryIn-person and virtual events just for HCPsLively expert panel discussions featuring peer-to-peer exchangesSubscribe to our eNewsletter for breaking news and curated content
Specialty
View MoreBreast CancerCAR T-cell TherapyChronic Lymphocytic LeukemiaGastrointestinal CancerGenitourinary CancersGynecologic OncologyImmuno-OncologyLung CancerMelanoma & Skin CancerMultiple MyelomaUrothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
Rare Cancer Series
Media
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Thoracic Night Live
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Subscribe
eNewsletter
Print Subscription
  • Advertise
  • About OncLive
  • Editorial Board
  • CancerNetwork.com
  • CGTlive.com
  • CureToday.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information

© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Spotlight
  • OncClub: Join the Chat on Trending Trials in Cancer
  • Complimentary print subscription for home or office delivery
  • In-person and virtual events just for HCPs
  • Lively expert panel discussions featuring peer-to-peer exchanges
  • Subscribe to our eNewsletter for breaking news and curated content
SpecialtySee All >
  • Breast Cancer
  • CAR T-cell Therapy
  • Chronic Lymphocytic Leukemia
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Oncology
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Multiple Myeloma
  • Urothelial Cancer
OncLive SOSS
  • Advertise
  • About OncLive
  • Editorial Board
  • CancerNetwork.com
  • CGTlive.com
  • CureToday.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Timothy S. Pardee, MD

  1. home

Articles

Dr. Pardee on CPI-613 for Patients With R/R AML

September 11th 2014

Timothy S. Pardee, MD, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).

Dr. Pardee Provides an Update on CPI-613

December 20th 2013

Timothy S. Pardee, MD, describes a phase I study of the first-in-class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies.

Dr. Pardee on CPI-613 in Hematologic Malignancies

July 10th 2013

Timothy S. Pardee, MD, describes a phase I trial looking at the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.